TY  - JOUR
T1  - Update on Hodgkin′s lymphoma
A1  - Robin Sabharwal
A1  - Shamindra Sengupta
A1  - Bhudev Sharma
A1  - Shivangi Gupta
JF  - Clinical Cancer Investigation Journal
JO  - Clin Cancer Investig J
SN  - 2278-0513
Y1  - 2013
VL  - 2
IS  - 2
DO  - 10.4103/2278-0513.113630
SP  - 106
EP  - 112
N2  - Lymphomas constitute approximately 5% of all malignant neoplasms of the head and neck. They are divided into two major subtypes, Hodgkin′s lymphomas (HLs) and non-HLs, depending on the presence or absence of Reed-Sternberg cells (RSCs). HL is a malignant tumor characterized by pleomorphic lymphocytic and histiocytic infiltrate with multinucleated RSCs. HL is regarded as encompassing two clearly defined entities according to the WHO classification: Nodular lymphocyte predominant HL and classical HL. These two entities differ in clinical features and behavior but, more importantly, in the pathological and biological features of their neoplastic and microenvironmental compartments. The etiology of HD remains unknown. Epstein-Barr virus (EBV) plays an important role in the pathogenesis of HL The diagnosis of HL is based on the finding of Reed-Sternberg cells (RSCs) in an appropriate cellular background of reactive lymphocytes and, in some cases fibrosis. The staging system for HL is the Ann Arbor staging system which was developed in 1971. This paper reviews the clinical presentation, classification, various variants and pathogenesis of HL.
UR  - https://ccij-online.org/article/update-on-hodgkin′s-lymphoma-95
ER  -